These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 29605222)

  • 1. Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease.
    Whitwell JL; Graff-Radford J; Tosakulwong N; Weigand SD; Machulda MM; Senjem ML; Spychalla AJ; Vemuri P; Jones DT; Drubach DA; Knopman DS; Boeve BF; Ertekin-Taner N; Petersen RC; Lowe VJ; Jack CR; Josephs KA
    Alzheimers Dement; 2018 Aug; 14(8):1005-1014. PubMed ID: 29605222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal and cross-sectional structural magnetic resonance imaging correlates of AV-1451 uptake.
    Das SR; Xie L; Wisse LEM; Ittyerah R; Tustison NJ; Dickerson BC; Yushkevich PA; Wolk DA;
    Neurobiol Aging; 2018 Jun; 66():49-58. PubMed ID: 29518752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimer's Disease.
    Tetzloff KA; Graff-Radford J; Martin PR; Tosakulwong N; Machulda MM; Duffy JR; Clark HM; Senjem ML; Schwarz CG; Spychalla AJ; Drubach DA; Jack CR; Lowe VJ; Josephs KA; Whitwell JL
    J Alzheimers Dis; 2018; 62(4):1713-1724. PubMed ID: 29614676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease.
    Lehmann M; Ghosh PM; Madison C; Laforce R; Corbetta-Rastelli C; Weiner MW; Greicius MD; Seeley WW; Gorno-Tempini ML; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2013 Mar; 136(Pt 3):844-58. PubMed ID: 23358601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease.
    Sintini I; Schwarz CG; Martin PR; Graff-Radford J; Machulda MM; Senjem ML; Reid RI; Spychalla AJ; Drubach DA; Lowe VJ; Jack CR; Josephs KA; Whitwell JL
    Hum Brain Mapp; 2019 Apr; 40(5):1618-1631. PubMed ID: 30549156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes.
    Sintini I; Graff-Radford J; Senjem ML; Schwarz CG; Machulda MM; Martin PR; Jones DT; Boeve BF; Knopman DS; Kantarci K; Petersen RC; Jack CR; Lowe VJ; Josephs KA; Whitwell JL
    Brain; 2020 Jul; 143(7):2281-2294. PubMed ID: 32572464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease.
    Strom A; Iaccarino L; Edwards L; Lesman-Segev OH; Soleimani-Meigooni DN; Pham J; Baker SL; Landau SM; Jagust WJ; Miller BL; Rosen HJ; Gorno-Tempini ML; Rabinovici GD; La Joie R;
    Brain; 2022 Apr; 145(2):713-728. PubMed ID: 34373896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease.
    Xia C; Makaretz SJ; Caso C; McGinnis S; Gomperts SN; Sepulcre J; Gomez-Isla T; Hyman BT; Schultz A; Vasdev N; Johnson KA; Dickerson BC
    JAMA Neurol; 2017 Apr; 74(4):427-436. PubMed ID: 28241163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visual cognition in non-amnestic Alzheimer's disease: Relations to tau, amyloid, and cortical atrophy.
    Putcha D; Brickhouse M; Touroutoglou A; Collins JA; Quimby M; Wong B; Eldaief M; Schultz A; El Fakhri G; Johnson K; Dickerson BC; McGinnis SM
    Neuroimage Clin; 2019; 23():101889. PubMed ID: 31200149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer's disease: a cohort study.
    Mattsson N; Ossenkoppele R; Smith R; Strandberg O; Ohlsson T; Jögi J; Palmqvist S; Stomrud E; Hansson O
    Alzheimers Res Ther; 2018 Aug; 10(1):77. PubMed ID: 30086796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease.
    Whitwell JL; Martin P; Graff-Radford J; Machulda MM; Senjem ML; Schwarz CG; Weigand SD; Spychalla AJ; Drubach DA; Jack CR; Lowe VJ; Josephs KA
    Alzheimers Dement; 2019 May; 15(5):675-685. PubMed ID: 30853465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal Spatial Relationships Between Atrophy and Hypometabolism Across the Alzheimer's Disease Continuum.
    Stocks J; Heywood A; Popuri K; Beg MF; Rosen H; Wang L;
    J Alzheimers Dis; 2023; 92(2):513-527. PubMed ID: 36776061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease.
    Phillips JS; Das SR; McMillan CT; Irwin DJ; Roll EE; Da Re F; Nasrallah IM; Wolk DA; Grossman M
    Hum Brain Mapp; 2018 Feb; 39(2):691-708. PubMed ID: 29105977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-sectional associations between [
    Teng E; Ward M; Manser PT; Sanabria-Bohorquez S; Ray RD; Wildsmith KR; Baker S; Kerchner GA; Weimer RM
    Neurobiol Aging; 2019 Sep; 81():138-145. PubMed ID: 31280117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microglial activation and tau burden predict cognitive decline in Alzheimer's disease.
    Malpetti M; Kievit RA; Passamonti L; Jones PS; Tsvetanov KA; Rittman T; Mak E; Nicastro N; Bevan-Jones WR; Su L; Hong YT; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
    Brain; 2020 May; 143(5):1588-1602. PubMed ID: 32380523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asymmetries of amyloid-β burden and neuronal dysfunction are positively correlated in Alzheimer's disease.
    Frings L; Hellwig S; Spehl TS; Bormann T; Buchert R; Vach W; Minkova L; Heimbach B; Klöppel S; Meyer PT
    Brain; 2015 Oct; 138(Pt 10):3089-99. PubMed ID: 26280595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease.
    Dronse J; Fliessbach K; Bischof GN; von Reutern B; Faber J; Hammes J; Kuhnert G; Neumaier B; Onur OA; Kukolja J; van Eimeren T; Jessen F; Fink GR; Klockgether T; Drzezga A
    J Alzheimers Dis; 2017; 55(2):465-471. PubMed ID: 27802224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau PET in Alzheimer disease and mild cognitive impairment.
    Cho H; Choi JY; Hwang MS; Lee JH; Kim YJ; Lee HM; Lyoo CH; Ryu YH; Lee MS
    Neurology; 2016 Jul; 87(4):375-83. PubMed ID: 27358341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting diagnosis and cognition with
    Mattsson N; Insel PS; Donohue M; Jögi J; Ossenkoppele R; Olsson T; Schöll M; Smith R; Hansson O
    Alzheimers Dement; 2019 Apr; 15(4):570-580. PubMed ID: 30639421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden.
    Rabinovici GD; Furst AJ; Alkalay A; Racine CA; O'Neil JP; Janabi M; Baker SL; Agarwal N; Bonasera SJ; Mormino EC; Weiner MW; Gorno-Tempini ML; Rosen HJ; Miller BL; Jagust WJ
    Brain; 2010 Feb; 133(Pt 2):512-28. PubMed ID: 20080878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.